Orforglipron
Peptide therapy: benefits, side effects, cost and protocols
C48H48F2N10O5
Orforglipron is an experimental oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable semaglutide and tirzepatide, it is a small molecule taken daily by mouth, potentially offering a more convenient weight loss and diabetes treatment option.
Sources: FDA / PubMed / ClinicalTrials.gov View
Who it's for
Who Orforglipron is usually considered for
- Oral administration (no injection)
- Weight loss potential
- Blood sugar regulation
- Convenient daily pill
Mechanism
How Orforglipron works
Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.
Evidence
Key studies
168 papers on PubMed
- 01
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
- 02
Wharton S, Aronne LJ, Stefanski A et al
N Engl J Med / Phase 3
Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks.
- 03
Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks
- 04
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
- 05
Horn DB, Ryan DH, Kis SG et al
Lancet / Phase 3
Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes.
- 06
Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes
- 07
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
- 08
Rosenstock J, Hsia S, Nevarez Ruiz L et al
N Engl J Med / Phase 3
Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo.
- 09
Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo
- 10
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study
Compound
Orforglipron compound data
- Formula
- C48H48F2N10O5
- Mol. weight
- 883.0 g/mol
- PubChem CID
- 137319706 ↗
- IUPAC
- 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one
FAQ
Orforglipron questions
What is ORFORGLIPRON?
Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist being developed by Eli Lilly. Currently in Phase 3 clinical trials, it could become the first oral non-peptide GLP-1 agonist if approved.
How does ORFORGLIPRON work?
Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.
Is ORFORGLIPRON legal to buy?
ORFORGLIPRON is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy ORFORGLIPRON?
ORFORGLIPRON is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does ORFORGLIPRON belong to?
ORFORGLIPRON is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of ORFORGLIPRON?
ORFORGLIPRON has been studied for: Oral administration (no injection), Weight loss potential, Blood sugar regulation, Convenient daily pill. Phase 3 trials by Eli Lilly. First oral non-peptide GLP-1 agonist if approved.
News
Orforglipron in the news
What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight-Loss Drug - University of Colorado Anschutz
University of Colorado Anschutz / 6 months ago
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist - Frontiers
Frontiers / 4 months ago
The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug - McGill University
McGill University / 6 months ago
Orforglipron: Australia’s first non-peptide oral GLP-1 - Medical Republic
Medical Republic / 4 days ago
newsGP - New oral GLP-1 to hit Australian shelves within days - Royal Australian College of General Practitioners (RACGP)
Royal Australian College of General Practitioners (RACGP) / 4 days ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Orforglipron?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.